Item 7.01 Regulation FD Disclosure.
The Company’s shareholders elected to redeem
an aggregate of 258 shares in connection with the Special Meeting. Following such redemptions and the deposit of the contribution described
above, the amount of funds remaining in the trust account is approximately $4.47 million. Accordingly, following such redemptions and
the deposit of the contribution of $0.08 per outstanding ordinary share, the Company has 1,816,475 ordinary shares issued and outstanding
(1,411,000 of which are shares held by our initial shareholders and are not subject to redemption) and the pro rata portion of the funds
available in the trust account is approximately $11.02 per public share.
On April 21, 2023, the Company issued a press
release, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K, announcing that the Company has extended the
period of time it will have to consummate its initial business combination by a further one month, or until May 23, 2023, and related
matters.
The information in this Item 7.01, including Exhibit
99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in such filing.
Additional Information
and Where to Find It
This Current Report relates
to a proposed business combination among Nukkleus, Brilliant and Merger Sub in which Merger Sub would merge into Brilliant. In connection
with the proposed transaction, Nukkleus has filed with the SEC a registration statement on Form S-4 that includes a proxy statement of
Nukkleus and that also constitutes a prospectus of Nukkleus with respect to the PubCo Shares to be issued in the proposed transaction
(the “proxy statement/prospectus”). The definitive proxy statement/prospectus (if and when available) will be delivered to
Nukkleus’s stockholders. Each of Nukkleus and Brilliant may also file other relevant documents regarding the proposed transaction
with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS OF NUKKLEUS AND BRILLIANT ARE URGED TO READ
THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS THAT ARE FILED WITH THE SEC IN CONNECTION WITH
THE PROPOSED TRANSACTION, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.
Investors and security
holders may obtain free copies of the proxy statement/prospectus (if and when available) and other documents that are filed or will be
filed with the SEC by Brilliant or Nukkleus through the website maintained by the SEC at www.sec.gov. Stockholders of Nukkleus will also
be able to obtain a copy of the definitive proxy statement, without charge by directing a request to: Nukkleus, Inc., 525 Washington Boulevard,
Jersey City, New Jersey 07310. Shareholders of Brilliant will also be able to obtain a copy of the definitive proxy statement, without
charge by directing a request to: Brilliant Acquisition Corporation, 99 Dan Ba Road, C-9, Putuo District, Shanghai, Peoples Republic of
China.
Participants in the
Solicitation
Brilliant and its directors
and executive officers are participants in the solicitation of proxies from the shareholders of Brilliant in respect of the proposed transaction.
Information about Brilliant’s directors and executive officers and their ownership of Brilliant’s ordinary shares is set forth
in Brilliant’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 10, 2023. Other information
regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or
otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC in respect of the
proposed transaction when they become available. You may obtain free copies of these documents as described in the preceding paragraph.
Nukkleus and its directors
and executive officers are participants in the solicitation of proxies from the shareholders of Nukkleus in respect of the proposed transaction.
Information about Nukkleus’s directors and executive officers and their ownership of Nukkleus common stock is set forth in Nukkleus’s
Annual Report on Form 10-K for the year ended September 30, 2022, filed with the SEC on April 10, 2023. Other information regarding the
participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will
be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC in respect of the proposed transaction
when they become available. You may obtain free copies of these documents as described above.
Cautionary Note Regarding
Forward-Looking Statements
Forward-looking statements
are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking
statements in this document, including but not limited to: (i) the risk that the proposed business combination may not be completed in
a timely manner or at all, which may adversely affect the price of Nukkleus and/or Brilliant securities; (ii) the risk that the proposed
business combination may not be completed by Brilliant’s business combination deadline and the potential failure to obtain an extension
of the business combination deadline if sought by Brilliant; (iii) the failure to satisfy the conditions to the consummation of the proposed
business combination, including the approval of the proposed business combination by the stockholders of Nukkleus and/or Brilliant, the
satisfaction of the minimum trust account amount following redemptions by Brilliant’s public shareholders and the receipt of certain
governmental and regulatory approvals; (iv) the effect of the announcement or pendency of the proposed business combination on Nukkleus’s
business relationships, performance, and business generally; (v) risks that the proposed business combination disrupts current plans of
Nukkleus and potential difficulties in Nukkleus employee retention as a result of the proposed business combination; (vi) the outcome
of any legal proceedings that may be instituted against Nukkleus or Brilliant related to the agreement and plan of merger or the proposed
business combination; (vii) the ability to maintain the listing of Brilliant’s securities on the Nasdaq Stock Market; (viii) the
price of Nukkleus’s and/or Brilliant’s securities, including volatility resulting from changes in the competitive and highly
regulated industries in which Nukkleus and Brilliant plan to operate, variations in performance across competitors, changes in laws and
regulations affecting Nukkleus’s business and changes in the combined capital structure; and (ix) the ability to implement business
plans, forecasts, and other expectations after the completion of the proposed business combination, and identify and realize additional
opportunities. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks
and uncertainties described in the proxy statement/prospectus contained in Nukkleus’s Form S-4 registration statement described
below, including those under “Risk Factors” therein, the Annual Report on Form 10-K for Nukkleus and Brilliant, Quarterly
Reports on Form 10-Q for Nukkleus and Brilliant and other documents filed by Nukkleus and/or Brilliant from time to time with the U.S.
Securities and Exchange Commission (the “SEC”). These filings identify and address other important risks and uncertainties
that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and
Nukkleus and Brilliant assume no obligation and, except as required by law, do not intend to update or revise these forward-looking statements,
whether as a result of new information, future events, or otherwise. Neither Nukkleus nor Brilliant gives any assurance that either Nukkleus
or Brilliant will achieve its expectations.
No Offer or Solicitation
This communication is
not intended to and will not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation
of any vote or approval and is not a substitute for the proxy statement/prospectus or any other document that Brilliant or Nukkleus may
file with the SEC or send to Nukkleus’s and/or Brilliant’s shareholders in connection with the proposed transaction. No offer
of securities will be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.